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Background: Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Cardiovascular (CV)
complications are the most common cause of death among ESRD patients. Beraprost sodium (BPS) is a prostacyclin
analog with vasodilatory and antiplatelet effects.
Methods: This is a multicenter prospective, randomized, double-blind, placebo-controlled trial to determine
whether treatment with BPS improves arterial stiffness in patients with type 2 diabetic nephropathy. A total of 102
participants with type 2 diabetic nephropathy will be screened, enrolled, and randomly assigned to receive either
80 μg BPS or placebo daily for 12 weeks. The primary outcome is the change in brachial-ankle pulse wave velocity
between baseline and after 12 weeks of medication use. The secondary outcomes will include changes in the
ankle-brachial index, the urine albumin to creatinine ratio, the estimated glomerular filtration rate, lipid profiles, and
blood pressure from baseline to after treatment.
Discussion: This clinical trial is the first to investigate the effects of BPS on changes in CV biomarkers, albuminuria,
renal function, and lipid profiles in patients with diabetic nephropathy.
Trial registration: ClinicalTrials.gov number NCT01796418
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The impact of diabetic nephropathy on the increasing
population with chronic kidney disease (CKD) and
end-stage renal disease (ESRD) is enormous. Diabetic
nephropathy has become the leading cause of ESRD
and is responsible for more than 40% of all cases in the
USA and South Korea [1,2]. Although randomized
studies have demonstrated that intensified multifactorial
intervention in patients with type 2 diabetes reduces the
risk of microangiopathy, cardiovascular (CV) events, and
mortality [3-5], the incidence of ESRD due to diabetes is
relentlessly increasing worldwide. CV complications are
the number one cause of death among patients with
ESRD [1,2]. Moreover, CV risk is not limited to ESRD,
and the risk of CV mortality begins to increase with even
a mild impairment of kidney function [6]. Therefore, early* Correspondence: cslimjy@snu.ac.kr
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reproduction in any medium, provided the ordetection and intervention for CV complications are
important to reduce mortality among patients with
CKD or ESRD due to diabetes. In this regard, surrogate
markers precisely estimating CV risk are essential. Pulse
wave velocity (PWV) and the ankle-brachial index (ABI)
are useful noninvasive biomarkers for predicting CV
risk [7]. PWV provides a measure of large artery stiff-
ness and has been reported as a risk factor for nonfatal
CV disease and CV mortality independent of systolic
blood pressure in dialysis patients [8,9]. The ABI is a cli-
nical tool for the detection of peripheral arterial disease
and the prediction of CV mortality and morbidity [10].
Beraprost sodium (BPS) is a stable orally active pros-
tacyclin (PGI2) analog. BPS acts by binding to PGI2
membrane receptors and inhibiting the release of Ca2+
from intracellular storage sites. These effects lead to
the relaxation of the smooth muscle cells and vasodila-
tion. BPS has also been suggested to improve micro-
vascular circulation through the reduction of red blood
cell deformability. Moreover, BPS alleviates vascular
thrombosis by inhibiting platelet aggregation. ThroughThis is an Open Access article distributed under the terms of the Creative
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to be an effective agent in the treatment of patients with
pulmonary arterial hypertension, Buerger’s disease, and
arteriosclerosis obliterans [11].
An in vitro experiment showed that BPS improved
endothelial function through the induction of nitric oxide
(NO) production and endothelial NO synthase activation
in endothelial cells [12]. In addition, BPS lowered serum
vascular cell adhesion molecule-1 levels and prevented the
increase of carotid intima-media thickness in patients with
type 2 diabetes, which suggested a beneficial effect of BPS
on the progression of atherosclerosis in diabetic patients
[13]. The development of arterial stiffness, as assessed by
PWV, has been prevented by BPS treatment in elderly
patients with cerebral infarction [14,15]. BPS has also
been shown to improve dyslipidemia and metabolic
syndrome in diabetic animal models [16,17]. A recent study
has reported that 8 weeks BPS treatment improves pain in
diabetic patients with painful peripheral neuropathy [18].
However, no studies have observed the effects of BPS on
CV biomarkers in diabetic nephropathy patients with a
high risk of CKD or ESRD.
Based on reports of the beneficial effects of BPS, we
hypothesize that BPS treatment will improve arterial
stiffness in diabetic nephropathy patients. To evaluate
this hypothesis, we will conduct this clinical trial in patients
with type 2 diabetic nephropathy.
Methods
Hypothesis
Treatment with BPS will improve arterial stiffness in
patients with type 2 diabetic nephropathy. Compared with
placebo-treated patients, arterial PWV will decrease in
BPS-treated patients.
Study design
This is a multicenter prospective, randomized, double-
blind, placebo-controlled trial. This study is an investigator-
initiated clinical trial. The study algorithm is shown in
Figure 1. After enrollment and treatment, clinical follow-up
will be conducted after 4 and 12 weeks of treatment.
Study participants
All patients aged 20 to 75 years with type 2 diabetes
mellitus will be screened. The following will be performed
at the initial visit: 1) questionnaire regarding past medical
history and drug history; 2) physical examination of all
systems; 3) measurement of height and weight; 4) blood
pressure and pulse rate measurement; and 5) collection of
blood and urine. Patients who meet all of the inclusion and
exclusion criteria and provide written informed consent are
eligible for this study (Table 1).
Serum and urine creatinine (Cr) will be measured using
the isotope dilution mass spectrometry-traceable methodon a Toshiba TBA 200FR Analyzer (Toshiba, Tokyo,
Japan). Urinary albumin will be measured using an
immunoturbidimetric assay on a Toshiba TBA 120FR
Analyzer. The estimated glomerular filtration rate (eGFR) is
calculated using the Modification of Diet in Renal Disease
formula. The formula was defined as follows, where
the serum Cr concentration is in mg/dL: eGFR = 175 ×
Cr−1.154 × Age−0.203 × (0.742 if female) [19].
Randomization
A research coordinator will perform the randomization
and deliver the study drugs. The participants and in-
vestigators will be blinded to the treatment assign-
ment. A list of random numbers will be generated by
an independent statistician and then used to randomly
allocate the treatments to equally sized treatment and
control groups. The randomization will be stratified on
the basis of sex and age, which will utilize a randomized
block design in blocks of four patients in the order of en-
rollment in each arm. A randomization code list will be
generated by a third party - the medical statistics support
team in the Seoul National University Boramae Medical
Center. The treatments will be allocated to the participants
in accordance with the predefined randomization list
(1:1 ratio for the treatment and control groups).
Treatments
After randomization, the participants will take either a
BPS (treatment group) or placebo (control group) pill
during the study. The tablet shapes and packaging of the
placebo pills are indistinguishable from those of the original
BPS pills. The BPS and placebo tablets are provided by
Astellas Pharma Korea, Inc. (Seoul, Korea). The pre-
scription and administration of the study drugs will be
performed in a double-blind manner. Based on the report
showing the prevention of arterial stiffness with BPS [14],
80 μg/day BPS in two divided doses will be administered to
the participants for 12 weeks. The administration of other
prostacyclin agents, such as limaprost alfadex, or fluori-
nated pyrimidine antifungal agents, such as flucytosine, will
be prohibited during the study. Participants with any
changes in antihypertensive, antiplatelet, or anticoagulant
medications during the study will be dropped. Investigators
or research coordinators will evaluate drug compliance in
the study participants, and participants with less than 80%
compliance will be dropped from the study.
Outcome measures
The primary outcome to be measured is the change in
the brachial-ankle PWV (ba-PWV) between baseline
and after 12 weeks of treatment. The secondary out-
comes will include changes in the ABI, urine albumin to
creatinine ratio, eGFR, lipid profiles, and blood pressure
from baseline to after treatment.
All patients with type 2 diabetic nephropathy
Assessed for eligibility
Excluded




Allocated to the treatment group
(BPS 80µg/day)









4 week follow-up 4 week follow-up
Post-treatment evaluation
Figure 1 Study algorithm. BPS, beraprost sodium.
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The physical examination and medication reviews will
be performed before treatment and after 4 and 12 weeks of
treatment. The laboratory evaluations, including a complete
blood count, Cr, total cholesterol, triglyceride, low-density
lipoprotein cholesterol, random urine albumin, and urine
Cr, will be performed at baseline and after 12 weeks of
treatment. ba-PWV and ABI will be measured using a Colin
pulse waveform analyzer (Colin CO, Ltd, Komaki, Japan)
at baseline and after 12 weeks of treatment. The study
schedule is shown in Figure 2.
Monitoring and safety assessments
Before the start of this trial, a central monitor will review
the study protocol and clinical research form (CRF) with
the investigators and research coordinators. During thestudy period, a monitor will regularly visit each institute
and evaluate the records of the participants, the CRF, com-
pliance with the study protocol and Good Clinical Practice
guidelines, and enrollment status. The storage, delivery,
and accountability of the study drug will also be monitored
during this period.
Any presence of bleeding, headache, hot flushes, shock,
interstitial pneumonia, abnormal liver function, hypersensi-
tivity reaction, angina, or gastrointestinal discomfort will be
recorded during treatment with BPS/placebo. All adverse
events, including serious adverse events (SAEs), will be
recorded and followed-up for the duration of the study
or until resolution. The assessment of adverse events will
be performed by investigators and research coordinators.
All SAEs will be graded and reported to the principal inves-
tigator and the ethics committee.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age between 20 and 75 years History of kidney transplantation
Type 2 diabetes using a glucose-lowering agent or insulin Advanced congestive heart failure (≥ NYHA class III)
Estimated GFR by the IDMS MDRD equation ≥30 ml/min/1.73 m2 Uncontrolled arrhythmia
More than two UACR ≥30 mg/g or UPCR≥ 300 mg/g in the most recent 6 months Advanced liver cirrhosis (Child-Pugh class C)
Blood pressure ≤140/90 mmHg without any additional antihypertensive
medications in the most recent 3 months
History of bleeding diathesis
Active infection or uncontrolled inflammatory disorders
History of cerebrovascular accident or myocardial infarction
Current use of an anticoagulant
Current use of more than two antiplatelet agents
Advanced malignancy (life expectancy ≤6 months)
Uncontrolled diabetes (HbA1C >10%)
Severe anemia (hemoglobin <8.0 g/dL)
Pregnancy or lactation
Genetic disease including galactose intolerance, lactose
deficiency, and glucose-galactose malabsorption
GFR, glomerular filtration rate; HbA1C, hemoglobin A1C; IDMS, isotope dilution mass spectrometry; MDRD, Modification of Diet in Renal Disease; NYHA, New York
Heart Association; UACR, urine albumin to creatinine ratio; UPCR, urine protein to creatinine ratio.
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No previous report has evaluated the effect of BPS on
arterial stiffness in diabetic patients. We therefore referred
to a study showing that the mean and standard deviation
of the PWV change due to BPS treatment in patients with
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Figure 2 Study schedule. ABI, ankle-brachial index; ba-PWV, brachial-ankle
Cr, creatinine; d, days; LDL, low-density lipoprotein; PR, pulse rate; R, random
to creatinine ratio; w, weeks.345 cm/s, respectively [14]. We adjusted the sample size
for an estimated drop-out rate of 25% due to poor compli-
ance, a two-sided level of significance of α = 5%, and a
power of 1-β = 90%, which indicated that 51 participants
will be required in each group to detect a significant
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ization; T-chol, total cholesterol; TG, triglycerides; UACR, urine albumin
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the analysis.
Statistical analyses
The statistical analyses will be performed both on per
protocol (PP) and intention-to-treat (ITT) bases. For the
PP analysis, all participants who completed the study and
were evaluated for the primary outcome will be included.
For the ITT analysis, all participants who signed the writ-
ten informed consent and were randomized into the study
will be included, regardless of whether the correct treat-
ment was administered. To evaluate the primary outcome,
a PP analysis will be performed for those participants who
showed a primary outcome variable among the targets for
the PP analysis. The secondary outcomes will be evaluated
in the participants who completed the study. For the
safety evaluation, all participants who signed the written
informed consent and were randomized to receive at least
one of the active treatments (BPS/placebo medication) will
be included in the analysis. The safety analysis will include
the calculation of the frequencies and rates of complications
and SAEs reported in the two groups.
The baseline clinical characteristics and laboratory data
of the study participants will be summarized in terms of
frequencies and percentages for categorical variables and
means with standard deviations for continuous variables.
Continuous variables will be analyzed using Student’s t test
or the Mann–Whitney U test. Chi-squared test or Fisher’s
exact test will be used for categorical variables. Differences
in the changes in the outcome measurement variables
between the treatment and control groups will be tested
with one-way analysis of variance. Differences in the
temporal changes in the outcome measurement variables
in each group will be analyzed with the paired t test or
Wilcoxon signed rank test. A value of P < 0.05 will be
considered to be statistically significant. All analyses will
be performed using SPSS (version 16.0. for Windows;
SPSS Inc., Chicago, IL, USA).
Ethical approval
This study will be performed in accordance with the
Declaration of Helsinki amended by the 59th World
Medical Association General Assembly in 2008. All of the
participants will sign a written informed consent stating
that participation is voluntary and that participation can be
withdrawn at any time, without any negative consequences
concerning their current or future medical treatment.
This study was approved by the Institutional Review
Board of Seoul National University Bundang Hospital,
Seoul National University Hospital, Seoul National
University Boramae Medical Center, Hallym University
Sacred Heart Hospital, and Kangnam Sacred Heart
Hospital. The trial protocol has been registered at http://
www.clinicaltrials.gov (NCT01796418).Discussion
Diabetic nephropathy is the number one cause of ESRD.
CV complications are the most common cause of death
in ESRD. Therefore, the early detection of CV risk using
biomarkers and the prevention of CV risk with an effective
drug are the only ways to improve the clinical outcomes
and mortality in patients with diabetic nephropathy. BPS,
a PGI2 analog, has shown many beneficial effects in both
preclinical and clinical studies. In this trial, we will test
whether BPS improves CV risk. This trial is the first to
investigate the effects of BPS on changes in CV biomarkers,
albuminuria, renal function, and lipid profiles in patients
with diabetic nephropathy.
Because BPS has the potential to increase bleeding risk
by inhibiting platelet aggregation, even patients on a single
antiplatelet agent appear to be in danger of bleeding after
their enrollment in this study. However, higher doses of
BPS administered for a longer duration compared with
this study were previously reported to not increase bleeding
risk. According to the study performed by Mohler and
colleagues [21], daily intake of 120 μg BPS with other
antiplatelet agents (aspirin, clopidogrel, or ticlopidine)
for 1 year was not associated with any bleeding event.
Furthermore, we will monitor and follow-up all adverse
events, including bleeding, for the duration of the study or
until resolution.
A 12-week study may be too short to demonstrate a
beneficial effect of BPS. To assess the sustained effects
of BPS on vascular benefits, long-term studies may be
needed. However, in New York Heart Association func-
tional class II and III patients with pulmonary arterial
hypertension, a 12-week treatment with BPS improved
exercise capacity and symptoms [22]. Moreover, the
main mechanism of BPS in the improvement of arterial
stiffness is through NO production, and BPS has a short
half-life [12]. We therefore hypothesize that short-term
treatment with BPS will improve arterial stiffness in this
study. If the beneficial effects of BPS are proven, BPS
could be used in clinical practice to improve CV and
renal outcomes in this high-risk population. Future clin-
ical trials with an extended administration of BPS over
52 weeks in a larger population will be required to de-
termine whether BPS improves the actual CV morbidity
and mortality.Trial status
This trial is ongoing. Participants are recruiting.
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